R&D Q2 clinical trials round-up: April to June 2025 The second quarter of 2025 has seen a surge of clinical trial activity across the pharmaceutical and biotech landscape.
R&D Advancements in early detection and innovative therapies tar... Alzheimer’s disease (AD) robs millions of individuals of their memories, cognitive function, and independence, placing an immense emotional and financial burden on families and healthcare s
News AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
